

# Epigenetics: Exposures, Genes & Generations

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.  
Director


National Institute of Environmental Health Sciences  
National Toxicology Program

30 October 2013




# The National Institute of Environmental Health Sciences

- One of the National Institutes of Health, but located in Research Triangle Park, NC
- Wide variety of programs supporting our mission of environmental health:
  - Intramural laboratories
  - Extramural funding programs
  - Disease Prevention
  - Clinical research program
  - National Toxicology Program
  - Public Health Focus




## A New Vision and Mission for NIEHS and NTP

- Our **vision** is to provide global leadership for innovative research that improves public health by preventing disease and disability
- Our **mission** is to discover how the environment affects people in order to promote healthier lives.



## Strategic Themes

- Studying **basic mechanisms** and **windows of susceptibility**
- Linking **individual and population exposure** to risk
- Creating better **predictive models** and 21<sup>st</sup> Century tools
- Enhancing **communication** and **diversity** in all aspects of research
- **Training** a multidisciplinary group of scientists
- Improving **coordination** between gov't agencies and other groups




## Toxicology for the 21<sup>st</sup> Century Goals....

- Identify patterns of compound-induced biological response in order to:
  - *characterize toxicity/disease pathways*
  - *facilitate cross-species extrapolation*
  - *model low-dose extrapolation*
- Prioritize compounds for more extensive toxicological evaluation
- Develop predictive models for biological response in humans



# Environmental burden of disease: moving beyond infectious agents and high exposures



## Why Environmental Health Matters

- 13 million deaths could be **prevented** per year by improving our environment
- Environmental factors influence 85 out of the 102 non-communicable diseases in WHO report
- Environmental factors account for at least 2/3 of cancer cases in the United States
- You can't change your genes, but you **CAN** change your environment



## “ENVIRONMENT” Includes:

- Industrial chemicals
- Agricultural chemicals
- Physical agents  
(heat, radiation)
- By-products of combustion  
and industrial processes  
(dioxin)
- Infectious agents
- Microbiome (gut flora)
- Foods and nutrients
- Prescription drugs
- Lifestyle choices and  
substance abuse
- Social and  
economic factors



## Ubiquitous Human Exposure

- Chemicals are *widely dispersed in our environment*
- Chemicals are often dispersed at biologically effective levels, exposure to humans is common
- Exposures do not occur singly
- One exposure can alter the body's response to other exposures
- Combinations must be studied
- The “Exposome” is the totality of exposures for a person




## New ways of thinking about environmental health sciences...

**OLD...** chemicals act by overwhelming the body's defenses by brute force at very high doses

**NEW...** chemicals can act like hormones and drugs to disrupt the control of development and function at very low doses to which the average person is exposed

**NEW...** susceptibility to disease persists long after exposure (**epigenetics**) and may lead to transgenerational effects




## ...and about disease causation

- Complex diseases have complex causes.
- Cancer and birth defects are not the only endpoints.
- The environment is a contributor to: obesity, diabetes, cardiopulmonary disease, autoimmune disease, reproductive dysfunction, neurodevelopmental disorders, schizophrenia, addiction, Alzheimer's Disease, and depression, and cancer and birth defects .




# Research Challenges in Environmental Health


- Investigating the **timing of exposure and windows of susceptibility**
- Measuring **individual biological responses** and accounting for **genetic susceptibility**
- Tying mechanisms such as **altered gene expression, epigenetic modifications**, to adverse health outcomes




# Developmental Origins of Disease: Developmental Exposures Lead to Disease Throughout Life




# Examples of Developmental Origins of Health and Disease (DOHAD)



# Mechanisms of inheritable epigenetics




# Timing of DNA methylation and de-methylation




## Cancer- DES and BPA


- Both Diethylstilbestrol (DES) and Bisphenol A (BPA) have been shown to cause epigenetic changes associated with cancer after *in utero* exposures




# In utero exposure to arsenic increases risk of COPD and lung cancer (Smith et al., 2006)



## Odds ratios for respiratory symptoms which exceeded 2.0 in the highest arsenic exposure



# Epigenetic modifications linked to arsenic




## Persistence of Effects

- Health effects of exposure can be observed **long after** the actual exposure has stopped
- This is especially true when exposures occur during growth and development, processes that are very sensitive to endocrine regulation
- Animal researchers discovered that endocrine disruptors can produce latent effects by subtly altering the structure of DNA molecules (epigenetics)
- The NIEHS is conducting human studies on the latent effects of EDC exposure, including studies of children with behavioral, mental and physical abnormalities who were exposed to phthalates, PAHs or flame retardants before birth



# Asthma

- Most cases of asthma are now thought to originate in early life



## Asthma - PAHs

- In utero* exposure to polycyclic aromatic hydrocarbons (PAHs) has been associated with altered methylation patterns and with childhood asthma

| Characteristics <sup>a</sup>      | PAH < 2.41 (N = 30) | PAH ≥ 2.41 (N = 26) | Subjects (N = 56) | Odds Ratios (95% CI's)        |
|-----------------------------------|---------------------|---------------------|-------------------|-------------------------------|
| Ethnicity (%AA)                   | 15 (50%)            | 15 (58%)            | 30 (54%)          | 1.4 (0.5, 3.9)                |
| Gender (% Males)                  | 12 (40%)            | 12 (46%)            | 24 (43%)          | 1.3 (0.4, 3.7)                |
| ACSL3 5'CGI Status (% Methylated) | 7 (23%)             | 21 (81%)            | 28 (50%)          | 13.8 (3.8, 50.2) <sup>b</sup> |

| ACSL3 5'CGI Methylation Status                                 | Methylated                              | Unmethylated                          | All                                     | Odds Ratios (95% CI's) |
|--|---|---------------------------------------|---|------------------------|
| Asthma (% Yes with asthma) <sup>a</sup>                        | 11/28 (39%)                             | 4/28 (14%)                            | 15/56 (27%)                             | 3.9 (1.1, 14.3)        |
| Median PAH exposure with in each group <sup>b</sup> (Min, Max) | 3.39 ng/m <sup>3</sup><br>(1.11, 34.48) | 1.7 ng/m <sup>3</sup><br>(0.49, 3.33) | 2.26 ng/m <sup>3</sup><br>(0.49, 34.48) |                        |

# Children's Research on Air Pollution and the Immune System

- Living within 75m of a major roadway associated with increased risk of asthma
- Genetic variations in immune response to air pollutants may increase susceptibility
- Children in a high-pollution environment showed impaired function of regulatory T cells compared to children in low-pollution setting
- Ambient air pollution may worsen asthma via an immune mechanism
- The pollution may mediate epigenetic changes in regulatory T cells (Nadeau, Journal of Allergy and Clinical Immunology, 2010)





# Windows of Susceptibility: Tobacco

- **Maternal Smoking & Children's Obesity**

- NTP Review of 23 Studies
- Studies range from 2001 – 2010
- Pooled data show:
  - OR=1.5 for obesity (95%CI=1.35-1.65)
  - OR=1.6 for overweight (95%CI=1.42-1.90)

Risk Estimate



 obese    
  overweight or overweight + obese    
  diabetes or risk for metabolic syndrome

## Chemical Obesogens

- Exposure to tobacco smoke *in utero* has been associated with obesity, hypertension, and gestational diabetes mellitus

**Table 4.** aORs<sup>a</sup> for obesity, hypertension, T2DM, and GDM by *in utero* exposure to tobacco smoke among women, stratified by adult smoking.<sup>b</sup>

| Outcomes         | Nonsmokers ( <i>n</i> = 51,852) |                   | Smokers ( <i>n</i> = 22,171) |                   | <i>p</i> -Interaction <sup>c</sup> |
|------------------|---------------------------------|-------------------|------------------------------|-------------------|------------------------------------|
|                  | Cases                           | aOR (95% CI)      | Cases                        | aOR (95% CI)      |                                    |
| Before pregnancy |                                 |                   |                              |                   |                                    |
| Obesity          | 4,565                           | 1.75 (1.64, 1.87) | 2,387                        | 1.29 (1.18, 1.40) | < 0.01                             |
| Hypertension     | 105                             | 1.48 (0.98, 2.23) | 31                           | 2.56 (1.23, 5.33) | 0.24                               |
| T2DM             | 91                              | 1.02 (0.64, 1.62) | 41                           | 1.38 (0.74, 2.56) | 0.38                               |
| GDM              | 385                             | 1.25 (1.00, 1.55) | 162                          | 1.48 (1.08, 2.02) | 0.33                               |

<sup>a</sup>Adjusted for woman's age and education. All models except for obesity were also adjusted for prepregnancy BMI (kg/m<sup>2</sup>).

<sup>b</sup>All models except for GDM were stratified by adult smoking before pregnancy; GDM model was stratified by adult smoking during pregnancy (*n* = 55,402 for nonsmokers and *n* = 18,250 for smokers). <sup>c</sup>Interaction term between *in utero* tobacco smoke (yes/no) and adult smoking (yes/no).

# Bisphenol A and Obesity in Children

**Table 2.** Association of Urinary Bisphenol A Concentration and Odds and Prevalence of Obesity in Strata Defined by Sample Characteristics<sup>a</sup>

|                    | Urinary Bisphenol A Concentration Quartile <sup>b</sup> |   |                           |                                  |                           |                                  |                           |                                   |                           |
|--------------------|---|---|---------------------------|----------------------------------|---------------------------|----------------------------------|---------------------------|-----------------------------------|---------------------------|
|                    | All   |   | 1<br>(n = 685)            | 2<br>(n = 700)                   | 3<br>(n = 737)            | 4<br>(n = 716)                   |                           |                                   |                           |
|                    | Unweighted<br>No.,<br>Obese/Total                       | Obese in<br>Stratum, %<br>(SE) <sup>c</sup> | Prevalence<br>(95% CI), % | OR<br>(95% CI)                   | Prevalence<br>(95% CI), % | OR<br>(95% CI)                   | Prevalence<br>(95% CI), % | OR<br>(95% CI)                    | Prevalence<br>(95% CI), % |
| Entire sample      | 590/2816  | 17.8 (1.3)                                  | 10.0<br>(7.6-12.5)        | 2.22<br>(1.53-3.23) <sup>d</sup> | 19.9<br>(15.0-24.7)       | 2.09<br>(1.48-2.95) <sup>d</sup> | 18.9<br>(14.8-23.0)       | 2.53<br>(1.72-3.74) <sup>d</sup>  | 22.1<br>(17.0-27.2)       |
| Sex                |   |   |                           |                                  |                           |                                  |                           |                                   |                           |
| Female             | 285/1366  | 16.5 (1.5)                                  | 10.8<br>(6.7-14.8)        | 1.86<br>(1.10-3.17) <sup>e</sup> | 18.4<br>(12.4 to 24.3)    | 1.65<br>(0.93-2.92)              | 16.6<br>(11.6-21.6)       | 2.00<br>(1.15-3.49) <sup>e</sup>  | 19.5<br>(13.5-25.5)       |
| Male               | 305/1450  | 19.0 (1.8)                                  | 9.4<br>(6.5-12.4)         | 2.63<br>(1.56-4.43) <sup>d</sup> | 21.6<br>(15.2-27.9)       | 2.56<br>(1.66-3.96) <sup>d</sup> | 21.1<br>(15.2-27.0)       | 3.14<br>(1.79-5.48) <sup>d</sup>  | 24.7<br>(17.2-32.1)       |
| Age group, y       |   |   |                           |                                  |                           |                                  |                           |                                   |                           |
| <12                | 227/1055  | 18.0 (1.6)                                  | 12.2<br>(6.8-17.5)        | 1.72<br>(1.05-2.81) <sup>e</sup> | 19.2<br>(11.7-26.6)       | 1.91<br>(1.14-3.21) <sup>e</sup> | 20.9<br>(15.1-26.6)       | 2.34<br>(1.31-4.18) <sup>e</sup>  | 24.3<br>(18.1-30.5)       |
| ≥12                | 363/1761  | 17.6 (1.5)                                  | 9.6<br>(6.1-13.1)         | 2.59<br>(1.49-4.48) <sup>f</sup> | 21.6<br>(15.7-27.5)       | 2.14<br>(1.25-3.64) <sup>f</sup> | 18.6<br>(13.3-23.8)       | 2.57<br>(1.55-4.23) <sup>f</sup>  | 21.5<br>(15.3-27.6)       |
| Race/ethnicity     |   |   |                           |                                  |                           |                                  |                           |                                   |                           |
| Hispanic           | 227/1004  | 23.2 (1.9)                                  | 22.4<br>(17.2-27.6)       | 1.24<br>(0.80-1.92)              | 26.5<br>(20.2-32.7)       | 0.94<br>(0.58-1.49)              | 21.3<br>(14.9-27.7)       | 1.02<br>(0.65-1.59)               | 22.8<br>(16.0-29.7)       |
| Non-Hispanic white | 124/787   | 15.5 (1.7)                                  | 4.7<br>(1.8-7.6)          | 4.32<br>(2.08-8.99) <sup>d</sup> | 17.5<br>(10.6-24.4)       | 4.21<br>(2.01-8.77) <sup>d</sup> | 17.1<br>(11.7-22.4)       | 6.03<br>(2.88-12.62) <sup>d</sup> | 22.8<br>(15.8-29.8)       |
| Non-Hispanic black | 216/893   | 24.5 (1.9)                                  | 20.8<br>(13.8-27.9)       | 0.99<br>(0.58-1.66)              | 20.7<br>(15.2-26.2)       | 1.38<br>(0.78-2.47)              | 26.8<br>(19.2-34.3)       | 1.34<br>(0.75-2.38)               | 26.1<br>(18.3-33.8)       |
| Other              | 23/132  | 10.3 (2.9)                                  | 7.1<br>(-2.4 to 16.7)     | 2.84<br>(0.64-12.4)              | 17.7<br>(3.8-31.7)        | 2.11<br>(0.30-14.8)              | 13.9<br>(0.5-27.3)        | 1.22<br>(0.25-5.86)               | 8.6<br>(2.5-14.6)         |

# Prenatal Pesticide Exposure Lowers Child IQ

## Prenatal Exposure to Organophosphate Pesticides and IQ in 7-Year Old Children

Maryse F. Bouchard, Jonathan Chevrier, Kim G. Harley,  
Katherine Kogut, Michelle Vedar, Norma Calderon,  
Celina Trujillo, Caroline Johnson, Asa Bradman,  
Dana Boyd Barr, Brenda Eskenazi



## 7-Year Neurodevelopmental Scores and Prenatal Exposure to Chlorpyrifos, a Common Agricultural Pesticide

Virginia Rauh, Srikes Arunajadai, Megan Horton,  
Frederica Perera, Lori Hoepner, Dana B. Barr, Robin Whyatt


## Prenatal Exposure to Organophosphates, Paraoxonase 1, and Cognitive Development in Childhood

Stephanie M. Engel, James Wetmur, Jia Chen, Chenbo Zhu,  
Dana Boyd Barr, Richard L. Canfield, and Mary S. Wolff



# Pesticide Exposure Linked to Risk of ADHD

**ORs for Any ADHD Subtype for 10-Fold Increases  
in Urinary DAP Metabolite Levels (N = 1139)**



Adjusted for gender, age, race/ethnicity, PIR, fasting duration, and logarithmically transformed urinary creatinine concentration.

# Chemicals with **Substantial** Evidence of Developmental Neurotoxicity (n≈100)

|                                   |                              |                              |
|-----------------------------------|------------------------------|------------------------------|
| 2-Ethoxyethyl Acetate             | Diazepam                     | Naltrexone                   |
| Acibenzolar- <i>S</i> -methyl     | Cytosine Arabinoside         | Nicotine                     |
| Acrylamide                        | DEET                         | Methoxyethanol, 2-           |
| Aldicarb                          | Deltamethrin                 | Methylazoxymethanol          |
| Allethrin                         | Diazinon                     | <b>Methylmercury</b>         |
| Aluminum (cl or lactate)          | Dieldrin                     | Ozone                        |
| Amino-nicotinamide(6-)            | Diethylstilbestrol           | Paraquat                     |
| Aminopterin                       | Diphenylhydantoin            | Parathion (ethyl)            |
| Amphetamine( <i>d</i> -)          | Epidermal Growth Factor      | <b>PBDEs</b>                 |
| <b>Arsenic</b>                    | Ethanol                      | <b>PCBs (generic)</b>        |
| Aspartame                         | Ethylene thiourea            | Penicillamine                |
| Azacytidine(5-)                   | Flourouracil(5-)             | Permethrin                   |
| Benomyl                           | Fluazinam                    | Phenylacetate                |
| Benzene                           | Fluoride                     | Phenylalanine (d,l)          |
| Bioallethrin                      | Griseofulvin                 | Phthalate, di-(2-ethylhexyl) |
| Bis(tri- <i>n</i> -butyltin)oxide | Haloperidol                  | Propylthiouracil             |
| Bisphenol A                       | Halothane                    | Retinoids/vit.A/isotretinoin |
| Bromodeoxyuridine(5-)             | Heptachlor                   | Salicylate                   |
| Butylated Hydroxy Anisol          | Hexachlorobenzene            | Tebuconazole                 |
| Butylated hydroxytoluene          | Hexachlorophene              | Tellurium (salts)            |
| Cadmium                           | Hydroxyurea                  | Terbutaline                  |
| Caffeine                          | Imminodipropionitrile (IDPN) | Thalidomide                  |
| Carbamazepine                     | Ketamine                     | THC                          |
| Carbaryl                          | <b>Lead</b>                  | Toluene                      |
| Carbon monoxide                   | Lindane                      | Triamcinolone                |
| Chlordecone                       | LSD                          | Tributyltin chloride         |
| Chlordiazepoxide                  | Maneb                        | Trichlorfon                  |
| Chlorine dioxide                  | Medroxyprogesterone          | Trichloroethylene            |
| Chlorpromazine                    | Mepivacaine                  | Triethyllead                 |
| Chlorpyrifos                      | Methadone                    | Triethyltin                  |
| Cocaine                           | Methanol                     | Trimethyltin                 |
| Colcemid                          | Methimazole                  | Trypan blue                  |
| Colchicine                        | Methylparathion              | Urethane                     |
| Cypermethrin                      | Monosodium Glutamate         | Valproate                    |
| Dexamethasone                     | MPTP                         | Vincristine                  |
| Diamorphine hydrochloride         | Naloxone                     |                              |

# Thank you!



NIEHS Strategic Plan Website  
<http://www.niehs.nih.gov/strategicplan>

